The newest recommendation of the American Society of
Clinical Oncology (ASCO) 2014 for HER2+ metastatic breast cancer patients
recommends the use of new drugs like pertuzumab and T-DM1 for first and second
line, respectively. The Perjecta costs is 6.000 USD a month and for
trastuzumab is 4500 USD a month. Thus, the costs for first line (without
including the costs for taxotere) will be over 10000 USD a month!. For the
T-DM1 (recommended second line), the drug will cost 9800 USD a month! … it is
clear that but the costs of such new medicines for
uninsured patients or 99% of patients from countries in development will be
impossible to afford! I strongly disagree with this!
© Luis Mendoza
Very good information The post is showing home remedies for Facelift Surgery Delhi
ReplyDelete